<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033305</url>
  </required_header>
  <id_info>
    <org_study_id>CYC-201</org_study_id>
    <nct_id>NCT01033305</nct_id>
  </id_info>
  <brief_title>Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapsule Formulation of Ciclosporin (CyCol™) in the Treatment of Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sigmoid Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sigmoid Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study in Ireland and United Kingdom to determine the effects, safety&#xD;
      and tolerability of a drug called CyCol™ in improving mild to moderate ulcerative colitis&#xD;
      (UC).&#xD;
&#xD;
      Informed consent will be obtained and following confirmation of eligibility and disease&#xD;
      assessment, study participants will be randomised (allocated by chance) to take either&#xD;
      CyCol™, or placebo, orally once every day for four weeks. Study visit assessments will&#xD;
      include blood and stool tests, physical examinations and flexible sigmoidoscopies (inspection&#xD;
      of the bowel wall using a flexible camera).&#xD;
&#xD;
      Half the participants will receive CyCol™ and half will receive placebo. At the end of&#xD;
      treatment (4 weeks) study participants will be reassessed again and the findings in those who&#xD;
      received CyCol™ will be compared with those who received placebo. Any side effects&#xD;
      experienced during the study and the safety of treatment with CyCol™ will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of CyCol™ in inducing clinical remission of mild to moderate Ulcerative Colitis.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Mild to Moderate Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CyCol™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CyCol™</intervention_name>
    <description>Orally, once per day for 4 weeks</description>
    <arm_group_label>CyCol™</arm_group_label>
    <other_name>Ciclosporin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally, once per day for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged &gt; 18 years&#xD;
&#xD;
          -  Diagnosis of mild to moderate diagnosis of UC involving at least the rectum and&#xD;
             sigmoid colon&#xD;
&#xD;
          -  Clinical severity assessed at screening using the Disease Activity Index (DAI)&#xD;
&#xD;
          -  Clinical severity documented and confirmed by flexible sigmoidoscopy, within 7 days of&#xD;
             starting study treatment&#xD;
&#xD;
          -  Signed and dated written informed consent.&#xD;
&#xD;
          -  Willing to maintain current UC medication dosing regimen from screening until the end&#xD;
             of the 4-week treatment period.&#xD;
&#xD;
          -  Able and willing to refrain from intake of St. Johns Wort or any other prescription,&#xD;
             over-the-counter, or herbal preparation that is known to affect cytochrome P450&#xD;
             metabolism throughout the 4-week treatment period.&#xD;
&#xD;
          -  Able and willing to refrain from intake of grapefruit or grapefruit juice or any other&#xD;
             food or drink that is known to affect cytochrome P450 metabolism throughout the 4 week&#xD;
             treatment period of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe or fulminant UC.&#xD;
&#xD;
          -  UC limited to rectum only.&#xD;
&#xD;
          -  Any previous colonic surgery.&#xD;
&#xD;
          -  Any histological evidence of dysplasia on colonoscopic biopsy.&#xD;
&#xD;
          -  Women of childbearing potential who are unable or unwilling to use adequate&#xD;
             contraceptive methods to avoid pregnancy.&#xD;
&#xD;
          -  Previous unsuccessful ciclosporin therapy.&#xD;
&#xD;
          -  Biologic therapy within the past 2 months prior to study treatment.&#xD;
&#xD;
          -  Methotrexate therapy within 4 weeks of study treatment.&#xD;
&#xD;
          -  A steroid treatment dose of greater than 10 mg/day prednisolone (or equivalent) within&#xD;
             4 weeks of study treatment.&#xD;
&#xD;
          -  Use of topical treatment (e.g. enemas) within 4 weeks of study treatment and unwilling&#xD;
             to refrain from use of topical treatments from the screening visit until the end of&#xD;
             the 4-week treatment period.&#xD;
&#xD;
          -  Significant renal impairment, hepatic impairment, uncontrolled hypertension,&#xD;
             premalignant skin lesions or current malignancies, or any other severe co-morbid&#xD;
             condition.&#xD;
&#xD;
          -  Known hypersensitivity to ciclosporin or any of its excipients.&#xD;
&#xD;
          -  Positive screening stool assay for Clostridium difficile, hemorrhagic E.coli 0157:H7,&#xD;
             Salmonella or Shigella&#xD;
&#xD;
          -  Diagnosis of Crohn's colitis, ischemic colitis, NSAID-induced colitis, or radiation&#xD;
             colitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diarmuid O'Donoghue, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart Bloom, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <state>Co. Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misercordiae University Hospital</name>
      <address>
        <city>Dublin 7</city>
        <state>Co. Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Co. Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Galway</city>
        <state>Co. Galway</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Adelaide and The Meath Hospital (Tallaght)</name>
      <address>
        <city>Tallaght</city>
        <state>Dublin</state>
        <zip>Dublin 24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidWestern Regional Hospital</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandwell and West MidlandsHospitals NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B71 4HJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conventry university Hospital</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool and Broadgreen University Hospitals NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital London</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College London</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mark's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Elliot hospital</name>
      <address>
        <city>Nuneaton</city>
        <zip>CV10 7DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliff Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sigmoidpharma.com</url>
    <description>company website</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

